Roivant Sciences Reports Q2 2026 Results with LISRAYA Commercial Launch and Positive Clinical Data
Roivant Sciences (ROIV) reported its second quarter 2026 financial results, highlighted by the successful commercial launch of LISRAYA, which generated $31.0 million in net product revenue during its first five weeks following August approval. The company also announced significant clinical milestones, including strong efficacy data for IMVT-1402 in rheumatoid arthritis and positive outcomes for brepocitinib in noninfectious uveitis trials. Financially, Roivant maintains a robust liquidity position with $4.2 billion in cash and marketable securities, bolstered by a $950 million initial settlement payment from Moderna litigation. While the company reported a loss from continuing operations of $153.0 million, this represents an improvement over the prior-year period. Management noted that while LISRAYA uptake is strong, some payer access challenges and pharmacy inventory dynamics may create modest headwinds in the upcoming quarter.
Topics: clinical trial results drug approval product revenue pulmonary hypertension rheumatoid arthritis share repurchases
Read the full article at Motley Fool
Part of the story Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data (3 articles)